CN112004810A - 一种氧代吡啶酰胺类衍生物的晶型及制备方法 - Google Patents

一种氧代吡啶酰胺类衍生物的晶型及制备方法 Download PDF

Info

Publication number
CN112004810A
CN112004810A CN201980027589.5A CN201980027589A CN112004810A CN 112004810 A CN112004810 A CN 112004810A CN 201980027589 A CN201980027589 A CN 201980027589A CN 112004810 A CN112004810 A CN 112004810A
Authority
CN
China
Prior art keywords
compound
formula
crystal form
powder diffraction
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980027589.5A
Other languages
English (en)
Other versions
CN112004810B (zh
Inventor
马亚辉
张浩宇
韩龙
邵启云
杜振兴
王捷
冯君
贺峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112004810A publication Critical patent/CN112004810A/zh
Application granted granted Critical
Publication of CN112004810B publication Critical patent/CN112004810B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明涉及一种氧代吡啶酰胺类衍生物的晶型及制备方法。具体地，本发明涉及式(I)化合物的A、B、C、D、E、F晶型及制备方法。本发明式(I)化合物的晶型具备良好的晶型稳定性，可更好地用于临床。
Figure DDA0002737496000000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980027589.5A 2018-07-02 2019-07-01 一种氧代吡啶酰胺类衍生物的晶型及制备方法 Active CN112004810B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810710037 2018-07-02
CN2018107100371 2018-07-02
PCT/CN2019/094170 WO2020007256A1 (zh) 2018-07-02 2019-07-01 一种氧代吡啶酰胺类衍生物的晶型及制备方法

Publications (2)

Publication Number Publication Date
CN112004810A true CN112004810A (zh) 2020-11-27
CN112004810B CN112004810B (zh) 2022-04-08

Family

ID=69059913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980027589.5A Active CN112004810B (zh) 2018-07-02 2019-07-01 一种氧代吡啶酰胺类衍生物的晶型及制备方法

Country Status (6)

Country Link
US (1) US11225462B2 (zh)
EP (1) EP3822264A4 (zh)
JP (1) JP2021529201A (zh)
KR (1) KR20210028232A (zh)
CN (1) CN112004810B (zh)
WO (1) WO2020007256A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041122A1 (zh) * 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
ATE230414T1 (de) 1998-02-12 2003-01-15 Molecumetics Ltd Mimetika von beta-faltblatt und verfahren zur verwendung davon
AU2003243657A1 (en) 2002-06-26 2004-01-19 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
IT1395963B1 (it) * 2009-06-04 2012-11-02 Rottapharm Spa Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
RS56168B1 (sr) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
KR102011534B1 (ko) 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 ＸＩａ 억제제로서 피리디논 및 피리미디논 유도체
US9765070B2 (en) 2013-10-30 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
ES2754599T3 (es) 2015-08-05 2020-04-20 Bristol Myers Squibb Co Nuevos inhibidores de FXIa derivados de glicina sustituidos
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
MX2021000256A (es) * 2018-07-19 2021-03-25 Jiangsu Hengrui Medicine Co Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.
WO2020180411A2 (en) 2019-01-23 2020-09-10 Integrated Lipid Biofuels Llc Genetically engineered yeast yarrowia lipolytica and methods for producing bio-based glycolic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041122A1 (zh) * 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
US11225462B2 (en) 2022-01-18
WO2020007256A1 (zh) 2020-01-09
JP2021529201A (ja) 2021-10-28
US20210122714A1 (en) 2021-04-29
EP3822264A1 (en) 2021-05-19
CN112004810B (zh) 2022-04-08
EP3822264A4 (en) 2021-11-10
KR20210028232A (ko) 2021-03-11

Similar Documents

Publication Publication Date Title
JP2023508482A (ja) スピロ環含有キナゾリン化合物
US9920034B2 (en) Crystalline forms of a factor XIa inhibitor
EA013080B1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
US11299462B2 (en) Crystal form of oxopicolinamide derivative and preparation method therefor
CN112004810B (zh) 一种氧代吡啶酰胺类衍生物的晶型及制备方法
US7388096B2 (en) Crystalline forms of a factor Xa inhibitor
CN115515938B (zh) FXIa抑制剂化合物的盐及其制备方法和医药用途
EP2691371B1 (en) Benzoic acid salt of otamixaban
CN114853762A (zh) 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
TWI722466B (zh) 氧代吡啶醯胺類衍生物的晶型及製備方法
CA2589886A1 (en) Crystalline forms of a factor xa inhibitor
EP3650450B1 (en) Crystal form ii of thienopyridine derivative bisulfate and preparation method therefor and use thereof
WO2023131017A1 (zh) 一种稠环衍生物的晶型、其制备方法及其应用
WO2023138647A1 (zh) 一种含硫异吲哚啉类衍生物的晶型
US20240150289A1 (en) Crystalline carbazole derivative
CN112778277B (zh) 环酮并吡啶酮联杂芳环化合物及其制备方法和用途
CN116789640A (zh) 达比加群酯共晶及其制备方法
CN117126148A (zh) 利伐沙班共晶及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40043085

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant